Clik here to view.
C. K. Cooper resumes coverage of healthcare
C. K. Cooper has resumed coverage on the healthcare sector with an initiation of Dusa Pharmaceuticals (NASDAQ:DUSA). “With the addition of Ken Trbovich in January of this year and, the re-initiation of...
View ArticleClik here to view.
C. K. Cooper starts Pozen at buy
C.K. Cooper has initiated coverage of Pozen (NASDAQ:POZN) with a “buy” rating and $11 price target based on the “potential value we expect Pozen to derive from a marketing agreement and FDA approval of...
View ArticleClik here to view.
C.K. Cooper starts Heska at buy
C.K. Cooper has initiated coverage of Heska (NASDAQ:HSKA) with a “buy” rating and $20 price target based on anticipated growth from Heska’s core companion animal business, driven by a rejuvenated sales...
View ArticleClik here to view.
Cooper hires Suraj Kalia in health care research
Suraj Kalia has joined investment banker C. K. Cooper as a managing director in the healthcare research department. Over the past 9 years, Mr. Kalia has focused primarily on medical device issuers,...
View ArticleClik here to view.
C.K. Cooper starts Durect at buy
C.K. Cooper has initiated coverage of Durect (NASDAQ:DRRX) with a “buy” rating and $3 price target, citing an anticipated “rebound in value we think may follow from Pfizer’s resubmission and FDA...
View ArticleClik here to view.
C.K. Cooper ups DUSA Pharma price target
C.K. Cooper has raised its price target for “buy-rated” DUSA Pharmaceuticals (NASDAQ:DUSA) to $9.50 from $8, suggesting that shareholders do not tender under a takeover offer from Mumbai-based Sun...
View Article
